» Articles » PMID: 36636072

Liver Resection for Hepatocellular Carcinoma Beyond the BCLC: Are Multinodular Disease, Portal Hypertension, and Portal System Invasion Real Contraindications?

Overview
Date 2023 Jan 13
PMID 36636072
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Barcelona Clinic Liver Cancer (BCLC) is a recognized guideline to standardize treatment allocation for hepatocellular carcinoma (HCC); however, many centers criticize its restrictive liver resection recommendations and have published good results after more liberal hepatectomy indications. The objective is to evaluate the results of HCC resection in a single center, with a more liberal indication for resection than proposed by the BCLC guideline. It was performed a retrospective cohort study including all patients who underwent liver resection for HCC in a single center between April 2008 and November 2018.

Methods: The results of 150 patients who underwent hepatectomy were evaluated and compared facing both 2010 and 2018 BCLC guidelines. Overall and disease-free survival after resection in patients with none, one, two, or three of the risk factors, as proposed by the BCLC, as contraindications to resection (portal hypertension, portal invasion, and more than one nodule) were analyzed.

Results: Nodule size and presence of portal invasion alone did not affect prognosis. If the BCLC 2010 and 2018 guidelines were followed, 46.7% and 26.7% of the patients, respectively, would not have received potentially curative treatment. The median overall and disease-free survival for patients with one BCLC contraindication factor were 43.3 and 15.1 months, respectively. The presence of two risk factors had a negative impact on overall survival (OS) and disease-free survival (DFS), although some patients had long-term survival. The only patient with the three risk factors had a poor outcome.

Conclusions: Selected patients with one BCLC contraindication factor may undergo resection with good results, whereas those with two factors should be allocated for hepatectomy only in favorable scenarios. Patients with the three risk factors do not appear to benefit from resection.

Citing Articles

Update on Resection Strategies for Hepatocellular Carcinoma: A Narrative Review.

Lee J, Choi H, Kim J, Lee T, Yoon Y Cancers (Basel). 2024; 16(23).

PMID: 39682279 PMC: 11640626. DOI: 10.3390/cancers16234093.


Exploring the role of liver resection as a first-line treatment option for multinodular BCLC-A hepatocellular carcinoma.

Oh J, Sinn D J Liver Cancer. 2024; 24(2):126-128.

PMID: 39188209 PMC: 11449570. DOI: 10.17998/jlc.2024.08.08.


Can indication of hepatic resection for hepatocellular carcinoma patients be expanded?.

Kubota K J Gastrointest Oncol. 2023; 14(4):1907-1908.

PMID: 37720448 PMC: 10502563. DOI: 10.21037/jgo-2022-03.

References
1.
Liu P, Lee Y, Hsia C, Hsu C, Huang Y, Chiou Y . Surgical resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. Ann Surg Oncol. 2014; 21(6):1825-33. DOI: 10.1245/s10434-014-3510-3. View

2.
Glantzounis G, Paliouras A, Stylianidi M, Milionis H, Tzimas P, Roukos D . The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review. Eur J Surg Oncol. 2017; 44(2):195-208. DOI: 10.1016/j.ejso.2017.11.022. View

3.
Glantzounis G, Karampa A, Peristeri D, Pappas-Gogos G, Tepelenis K, Tzimas P . Recent advances in the surgical management of hepatocellular carcinoma. Ann Gastroenterol. 2021; 34(4):453-465. PMC: 8276352. DOI: 10.20524/aog.2021.0632. View

4.
Guo H, Wu T, Lu Q, Li M, Guo J, Shen Y . Surgical resection improves long-term survival of patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages. Cancer Manag Res. 2018; 10:361-369. PMC: 5827460. DOI: 10.2147/CMAR.S152707. View

5.
Ruzzenente A, Capra F, Pachera S, Iacono C, Piccirillo G, Lunardi M . Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients. J Gastrointest Surg. 2009; 13(7):1313-20. DOI: 10.1007/s11605-009-0903-x. View